SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345357.
  • 2
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165176.
  • 3
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 35973602.
  • 4
    Kong YY, Boyle WJ, Penninger JM 1999 Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation and lymphocyte development. Immunol Cell Biol 77: 188193.
  • 5
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315323.
  • 6
    Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ 2000 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97: 15661571.
  • 7
    Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K 1998 RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253: 395400.
  • 8
    Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB 1998 Characterization of the intracellular domain of receptor activator of NF-κB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase. J Biol Chem 273: 2055120555.
  • 9
    Darnay BG, Ni J, Moore PA, Aggarwal BB 1999 Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 274: 77247731.
  • 10
    Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC 1998 The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J Biol Chem 273: 3412034127.
  • 11
    Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der Heiden A, Itie A, Wakeham A, Khoo W, Sasaki T, Cao Z, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, Mak TW 1999 TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13: 10151024.
  • 12
    Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R 1997 Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 3: 12851289.
  • 13
    Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U 1997 Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11: 34823496.
  • 14
    Verma IM, Stevenson J 1997 IkappaB kinase: Beginning, not the end. Proc Natl Acad Sci USA 94: 1175811760.
  • 15
    Karin M 1999 The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol Chem 274: 2733927342.
  • 16
    Ghosh S 1999 Regulation of inducible gene expression by the transcription factor NF-kappaB. Immunol Res 19: 183189.
  • 17
    Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM 1999 Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 284: 321325.
  • 18
    Li Q, Lu Q, Hwang JY, Buscher D, Lee KF, Izpisua-Belmonte JC, Verma IM 1999 IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev 13: 13221328.
  • 19
    Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R, Karin M 1999 The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 189: 18391845.
  • 20
    Rudolph D, Yeh WC, Wakeham A, Rudolph B, Nallainathan D, Potter J, Elia AJ, Mak TW 2000 Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes Dev 14: 854862.
  • 21
    Yamamoto A, Miyazaki T, Kadono Y, Takayanagi H, Miura T, Nishina H, Katada T, Wakabayashi K, Oda H, Nakamura K, Tanaka S 2002 Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand. J Bone Miner Res 17: 612621.
  • 22
    Sherr CJ 1994 G1 phase progression: Cycling on cue. Cell 79: 551555.
  • 23
    Sherr CJ, Roberts JM 1999 CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 13: 15011512.
  • 24
    Vidal A, Koff A 2000 Cell-cycle inhibitors: Three families united by a common cause. Gene 247: 115.
  • 25
    Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T 2000 Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191: 275286.
  • 26
    Lin J, Jinno S, Okayama H 2001 Cdk6-cyclin D3 complex evades inhibition by inhibitor proteins and uniquely controls cell's proliferation competence. Oncogene 20: 20002009.
  • 27
    Meyerson M, Enders GH, Wu CL, Su LK, Gorka C, Nelson C, Harlow E, Tsai LH 1992 A family of human cdc2-related protein kinases. EMBO J 11: 29092917.
  • 28
    Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF 1992 Bone and haematopoietic defects in mice lacking c-fos. Nature 360: 741745.
  • 29
    Johnson RS, Spiegelman BM, Papaioannou V 1992 Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71: 577586.
  • 30
    Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF 1994 c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266: 443448.
  • 31
    Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF 2000 Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 24: 184187.
  • 32
    Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M 2000 Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 275: 3115531161.
  • 33
    Fuller K, Lean JM, Bayley KE, Wani MR, Chambers TJ 2000 A role for TGFbeta(1) in osteoclast differentiation and survival. J Cell Sci 113: 24452453.
  • 34
    Kaneda T, Nojima T, Nakagawa M, Ogasawara A, Kaneko H, Sato T, Mano H, Kumegawa M, Hakeda Y 2000 Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappaB ligand and macrophage-colony-stimulating factor. J Immunol 165: 42544263.
  • 35
    Baldin V, Lucus J, Marcote MJ, Pagano M, Draetta G 1993 Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7: 812821.
  • 36
    Hengstchlager M, Braun K, Soucek A, Miloloza E, Hengstchlager O 1999 Cyclin-dependent kinases at the G1-S transition of the mammalian cell cycle. Mutat Res 436: 19.
  • 37
    Chen Q, Lin J, Jinno S, Okayama H 2003 Overexpression of Cdk6-cyclin D3 highly sensitizes cells to physical and chemical transformation. Oncogene 22: 9921001.
  • 38
    Swanton C, Mann DJ, Fleckenstein B, Neipel F, Peters G, Jones N 1997 Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 390: 184187.
  • 39
    Tanaka K, Okayama H 2000 A pcl-like cyclin activates the Res2p-Cdc10p cell cycle “start” transcriptional factor complex in fission yeast. Mol Biol Cell 11: 28452862.
  • 40
    Missero C, Di Cunto F, Kiyokawa H, Koff A, Dotto GP 1996 The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev 10: 30653075.
  • 41
    Deng C, Zhang P, Harper JW, Elledge SJ, Leder P 1995 Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675684.
  • 42
    Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, el-Houseini ME 1994 Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 9: 33893396.
  • 43
    Schwaller J, Koeffler HP, Niklaus G, Loetscher P, Nagel S, Fey MF, Tobler A 1995 Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells. J Clin Invest 95: 973979.
  • 44
    Freemerman AJ, Vrana JA, Tombes RM, Jiang H, Chellappan SP, Fisher PB, Grant S 1997 Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60). Leukemia 11: 504513.
  • 45
    Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP 1996 Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10: 142153.
  • 46
    Muto A, Kizaki M, Yamato K, Kawai Y, Kamata-Matsushita M, Ueno H, Ohguchi M, Nishihara T, Koeffler HP, Ikeda Y 1999 1,25-dihydroxyvitamin D3 induces differentiation of a retinoic acid-resistant acute promyelocytic leukemia cell line (UF-1) associated with expression of p21(WAF1/CIP1) and p27(KIP1). Blood 93: 22252233.
  • 47
    Okahashi N, Murase Y, Koseki T, Sato T, Yamato K, Nishihara T 2001 Osteoclast differentiation is associated with transient upregulation of cyclin-dependent kinase inhibitors p21(WAF1/CIP1) and p27(KIP1). J Cell Biochem 80: 339345.
  • 48
    Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY 1996 Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707720.
  • 49
    Yan Y, Frisen J, Lee MH, Massague J, Barbacid M 1997 Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev 11: 973983.
  • 50
    Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA, Elledge SJ 1997 Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 387: 151158.
  • 51
    Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T 2002 Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3: 889901.
  • 52
    Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y, Kumegawa M, Kimura T, Takeya T 2002 Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 277: 4114741156.